Clovis Oncology announces positive hearing for Rubraca in Europe

Clovis Oncology announces positive hearing for Rubraca in Europe

BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153... Read More

Wednesday December 5, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy, Rucaparib

Clovis Oncology announces second patent for Rucaparib high dose

Clovis Oncology announces second patent for Rucaparib high dose

BOULDER -- Clovis Oncology , Inc. (NASDAQ:CLVS) today announced the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating... Read More

Tuesday November 20, 2018 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy

Clovis Oncology receives Breakthrough Therapy designation for Rubraca

Clovis Oncology receives Breakthrough Therapy designation for Rubraca

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced theU.S. Food and Drug Administration(FDA) has granted Breakthrough Therapy designation for Rubraca (rucaparib) as a monotherapy... Read More

Tuesday October 2, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy, FDA

Clovis Oncology announces first patient enrolled in cancer trial

Clovis Oncology announces first patient enrolled in cancer trial

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis Rubraca (rucaparib), a... Read More

Wednesday August 8, 2018 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy

Clovis Oncology receives European validation for Rubraca cancer drug

Clovis Oncology receives European validation for Rubraca cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the European Medicines Agency (EMA) has validated the application for a Type II variation to the marketing authorization for Rubraca ... Read More

Thursday July 5, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology announces European authorization of rucaparib for ovarian cancer care

Clovis Oncology announces European authorization of rucaparib for ovarian cancer care

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with... Read More

Tuesday May 29, 2018 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rucaparib

Clovis Oncology announces FDA approval of Rubraca for ovarian cancer treatment

Clovis Oncology announces FDA approval of Rubraca for ovarian cancer treatment

BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) announced the U.S. Food and Drug Administration (FDA) approved Rubraca (rucaparib) tablets for the maintenance treatment of adult patients with... Read More

Monday April 9, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology’s Rubraca cancer treatment gets green light from EU

Clovis Oncology’s Rubraca cancer treatment gets green light from EU

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the European Unions (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive... Read More

Monday March 26, 2018 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy